PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Intervirology10.1159/0000749902003466344-349Viral Breakthrough during Lamivudine Therapy for Chronic Hepatitis BNancy Leunghttps://www.karger.com/Article/Pdf/74990, https://www.karger.com/Article/Pdf/74990
Journal of Hepatology10.1016/j.jhep.2004.04.0322004413454-461Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutantsChien-Hung Chen, Chuan-Mo Lee, Sheng-Nan Lu, Jing-Houng Wang, Hung-Da Tung, Chao-Hung Hung, Wei-Jen Chen, Chi-Sin Changchienhttps://api.elsevier.com/content/article/PII:S0168827804002247?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827804002247?httpAccept=text/plain
Liver Transplantation10.1053/jlts.2002.3673420028121198-1199Rhabdomyolytic syndrome during the lamivudine therapy for acute exacerbation of chronic type B hepatitisKaichiro Yahagi, Yoshiyuki Ueno, Yutaka Mano, Tooru Shimosegawahttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1053%2Fjlts.2002.36734, https://onlinelibrary.wiley.com/doi/full/10.1053/jlts.2002.36734
Intervirology10.1159/0003657572014576337-343The Feasibility of Discontinuing Lamivudine in Lamivudine-Resistant Chronic Hepatitis B Patients on Lamivudine and Adefovir Combination TherapySeong Min Chung, Young-Sang Byoun, Hee-Sup Kim, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeonghttps://www.karger.com/Article/Pdf/365757, https://www.karger.com/Article/Pdf/365757
International Journal of Clinical Practice10.1111/j.1742-1241.2004.00266.x200458111088-1091Acute leukaemia in chronic hepatitis B patients with lamivudine therapyR-N. Chien, C-T. Yeh, P-N. Wang, M-C. Kuo, S-Y. Hsieh, L-Y. Shih, Y-F. Liawhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1742-1241.2004.00266.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1742-1241.2004.00266.x/fullpdf
Journal of Hepatology10.1016/s0168-8278(02)00419-12003383322-327The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis BRong-Nan Chien, Chia-Hsien Lin, Yun-Fan Liawhttps://api.elsevier.com/content/article/PII:S0168827802004191?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827802004191?httpAccept=text/plain
Hepatology Research10.1016/s1386-6346(01)00135-82002223223-230Lamivudine treatment for acute exacerbation of hepatitis B in patients undergoing immunosuppressive therapyN Kanaihttps://api.elsevier.com/content/article/PII:S1386-6346(01)00135-8?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1386-6346(01)00135-8?httpAccept=text/plain
Journal of Hepatology10.1016/s0168-8278(04)90425-4200440126425 Lowest serum hepatitis B virus DNA level is predicable factor for viral breakthrough during lamivudine therapy in chronic hepatitis B patientsM. Cho, J. Heo, D.Y. Lyu, B.M. Cho, H.H. Kim, G.H. Kim, D.H. Kang, G.A. Song, U.S. Yanghttps://api.elsevier.com/content/article/PII:S0168827804904254?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827804904254?httpAccept=text/plain
Hepatology10.1053/jhep.2000.163332000323635-639Acute Exacerbation of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine TherapyPieter Honkoop, Robert A. de Man, Hubert G.M. Niesters, Pieter E. Zondervan, Solko W. Schalmhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1053%2Fjhep.2000.16333
Journal of Hepatology10.1016/s0168-8278(01)80565-12001340155Durability of HBEAG seroconversion in chronic hepatitis B patients after lamivudine A-interferon or lamivudine A-interferon combination therapyA Van Nunenhttps://api.elsevier.com/content/article/PII:S0168-8278(01)80565-1?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168-8278(01)80565-1?httpAccept=text/plain